biotech Archives

🚀 Register to Join “Food Shouldn’t Hurt: EoE, Eupraxia, and a Promising New Treatment Approach” – (Friday, August 21 at 8:30am PT)

by John F. Heerdink, Jr. August 20, 2026 268Views 0Likes

Tribe Public (www.TribePublic.com) is welcoming James A. Helliwell, M.D., Co-Founder and Chief Executive Officer of Eupraxia Pharmaceuticals (NASDAQ: EPRX), for a timely discussion of Eupraxia’s work in EoE, its proprietary Diffusphere™ drug-delivery platform, and the potential opportunity ahead. Dr. Helliwell brings an…

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

by John F. Heerdink, Jr. July 20, 2026 171Views 0Likes

Eupraxia Pharmaceuticals, Inc. (NASDAQ: EPRX) is quietly setting up one of the more intriguing biotech inflection points on Wall Street as it marches toward Phase 2b data for EP‑104GI in eosinophilic esophagitis (EoE) this December, with investors increasingly framing the “bar” in…

Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI )

by John F. Heerdink, Jr. July 13, 2026 286Views 0Likes

Agenus Inc. (NASDAQ: AGEN) and Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, TSX: EPRX) just offered Wall Street a reminder that in biotech, capital and human capital still set the tempo—one via an oversubscribed private placement, the other via a board refresh that reads…

Biotech Sizzles While Beef Soars: Why Investors Are Buying Labs, Not Ribeyes -( $AMWL $EPRX $MODD $XBI )

by John F. Heerdink, Jr. July 11, 2026 336Views 0Likes

Beef is getting pricier just as biotech is getting hotter, and for investors willing to look past the grocery aisle to the lab bench, that may be the more interesting inflation story. From Ribeye Shock to Risk-On: The Macro Backdrop Consumers may…

Biotech, Insulin Pumps, & Power Boards: Four Chronic‑Care Plays Quietly Rewriting the Healthcare Script -( $ABVX $LLY $MMED $MODD )

by John F. Heerdink, Jr. June 30, 2026 335Views 0Likes

Wall Street’s biotech and medtech set is quietly stitching together a new playbook for chronic disease – one that blends Phase 3 data, insulin hardware, boardroom star power, and China oncology. Ulcerative Colitis: Abivax Steps Onto Center Stage French biotech Abivax SA…

Biotech Dealmaking & IPO Boom: What 2026’s $100 Billion Wave Means For Investors -( $AKTS $EIKN $IBB $MANE $SPTS $XBI )

by John F. Heerdink, Jr. June 18, 2026 398Views 0Likes

Biotech dealmaking is back in full swing, and for once, Wall Street’s punchline isn’t that the scientists made all the money and the shareholders got the placebo. Biotech’s $100 Billion Revival Biopharma M&A has roared back in 2026, with announced biotech and…

Lilly’s Ascidian Bet and NewLimit’s ‘Anti-Aging’ $3B Valuation Show Biotech’s Newest Obsession: Rewriting Biology Itself -( $COIN $LLY $XBI )

by John F. Heerdink, Jr. June 3, 2026 435Views 0Likes

The market is rewarding platforms that promise to rewrite instructions rather than merely manage symptoms. Eli Lilly and Company (LLY) is teaming up with privately held Ascidian Therapeutics in a deal valued at up to $1.9 billion, giving Lilly exclusive, target-specific rights…

FDA Musical Chairs: What the Latest Leadership Shuffle Means for Biotech Investors -( $IBB $XBI )

by John F. Heerdink, Jr. May 16, 2026 429Views 0Likes

The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors. FDA’s New Cast at the Top The Food…

Family Offices Put On The White Coat: Why The Smart Money Is Suddenly Fluent In AI & Oncology

by John F. Heerdink, Jr. May 12, 2026 419Views 0Likes

Family offices didn’t just come back to the deal table in April – they showed up with term sheets in one hand and stethoscopes in the other. Healthcare Becomes the New Family Office Heirloom After a cautious March tied to geopolitical jitters…

Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB )

by John F. Heerdink, Jr. April 29, 2026 322Views 0Likes

In a market where capital efficiency has become the new currency of credibility, Eli Lilly & Co. (LLY) appears to be writing a decidedly modern playbook for growth—one acquisition at a time. The Indianapolis-based pharmaceutical heavyweight has quietly assembled a portfolio of…

Tag: biotech

🚀 Register to Join “Food Shouldn’t Hurt: EoE, Eupraxia, and a Promising New Treatment Approach” – (Friday, August 21 at 8:30am PT)

The Esophagus Economy: How EP‑104GI Could Reshape EoE Treatment—and Eupraxia’s Valuation -( $EPRX $REGN $SNY )

Cash, Catalysts and Credentials: Why Agenus and Eupraxia Are Starting to Screen In -( $AGEN $EPRX $XBI )

Biotech Sizzles While Beef Soars: Why Investors Are Buying Labs, Not Ribeyes -( $AMWL $EPRX $MODD $XBI )

Biotech, Insulin Pumps, & Power Boards: Four Chronic‑Care Plays Quietly Rewriting the Healthcare Script -( $ABVX $LLY $MMED $MODD )

Biotech Dealmaking & IPO Boom: What 2026’s $100 Billion Wave Means For Investors -( $AKTS $EIKN $IBB $MANE $SPTS $XBI )

Lilly’s Ascidian Bet and NewLimit’s ‘Anti-Aging’ $3B Valuation Show Biotech’s Newest Obsession: Rewriting Biology Itself -( $COIN $LLY $XBI )

FDA Musical Chairs: What the Latest Leadership Shuffle Means for Biotech Investors -( $IBB $XBI )

Family Offices Put On The White Coat: Why The Smart Money Is Suddenly Fluent In AI & Oncology

Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB )

Your Guide To Staying Informed In The Markets